Identification of saquinavir as a potent inhibitor of dimeric SARS-CoV2 main protease through MM/GBSA

CURRENT STATUS: Posted

Prescreen

10.21203/rs.3.rs-27406/v1

Subject Areas

Biophysics Bioinformatics

Keywords
Protease, SARS-CoV2, COVID-19, Docking, MD simulations
Abstract

Among targets selected for studies aimed to identify potential inhibitors against COVID-19, SARS-CoV2 main proteinase (M\text{pro}) is highlighted. M\text{pro} is indispensable for virus replication, and is a promising target of potential inhibitors of COVID-19. Recently, monomeric SARS-CoV2 M\text{pro}, drug repurposing and docking methods have facilitated the identification of several potential inhibitors. Results were refined through the assessment of dimeric SARS-CoV2 M\text{pro}, which represents the functional state of enzyme. Docking and molecular dynamics (MD) simulations combined with molecular mechanics/generalized Born surface area (MM/GBSA) studies indicated that dimeric M\text{pro} most significantly impacts binding affinity tendency compared with the monomeric state, which suggesting that dimeric state is most useful when performing studies aimed to identify drugs targeting M\text{pro}. In this study, we extend previous research by performing docking and MD simulation studies coupled with an MM/GBSA approach to assess binding of dimeric SARS-CoV2 M\text{pro} to 12 FDA-approved drugs (darunavir, indinavir, saquinavir, tipranavir, diosmin, hesperidin, rutin, raltegravir, velpatasvir, ledipasvir, rosuvastatin and bortezomib), which were identified as the best candidates for treatment of COVID-19 in some previous dockings studies involving monomeric SARS-CoV2 M\text{pro}. This analysis identified saquinavir as a potent inhibitor of dimeric SARS-CoV2 M\text{pro}, therefore, the compound may have clinical utility against COVID-19.

1. Introduction

The outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) was first reported on December 30, 2019 in Wuhan China [1]. SARS-CoV2 belongs to the beta coronavirus group, and is similar to SARS-coronaviruses. The disease caused by SARS-CoV2 was named coronavirus disease 2019 (COVID-19) by World Health Organization, and represents a grave menace to global public health and local economies. As of May 2, 2020, over 3,362,778 cases of COVID-19 have been reported in 187 countries, and has caused 239,227 total deaths (https://coronavirus.jhu.edu/map.html). Therefore, we must urgently identify effective, available, and affordable drugs to treat COVID-19 to reduce the toll of the epidemic.

A potential treatment for COVID-19 involves combining two HIV-1 protease inhibitors (lopinavir and ritonavir), which have been useful against severe acute respiratory syndrome coronavirus (SARS-CoV) [2] via targeting SARS-CoV main proteinase (SARS-CoV M\text{pro}) [3]. SARS-CoV M\text{pro} mediates replicase polyprotein proteolytic activity, which is essential for viral replication, and represents an important target for reducing the impact of COVID-19. Alignment of SARS-CoV M\text{pro} and SARS-CoV2 main proteinase showed that both proteins share up to 95% sequence identity, suggesting that SARS-CoV M\text{pro} inhibitors may function similarly against SARS-CoV2 M\text{pro}. Theoretical methods repurposed from studies of SARS-CoV M\text{pro} have been used to identify FDA-approved small ligands that are potential inhibitors of monomeric SARS-CoV2 M\text{pro} [4,5]. Additional theoretical studies comparing binding to dimeric forms of SARS-CoV M\text{pro} and SARS-CoV2 M\text{pro}, which is the active form of the enzyme [6]. This highlighted differences between binding affinities of monomeric versus dimeric forms of SARS-CoV M\text{pro} or SARS-CoV2 M\text{pro}, and revealed that praziquantel (first option) and parapanel (second option) may be useful for treating COVID-19 via inhibition of SARS-CoV-2 M\text{pro} [7]. In addition, previous work demonstrated that docking and MD simulations should be performed using homodimeric, rather than monomeric, SARS-CoV2 M\text{pro}.

Here, we elaborate upon previous research by performing docking and MD simulation studies coupled with the molecular mechanics/generalized Born surface area (MM/GBSA) to assess binding of dimeric SARS-CoV2 M\text{pro} to 12 FDA-approved drugs, which were identified as being the most attractive candidates for treatment of COVID-19 in previous studies that virtually screened candidates targeting monomeric SARS-CoV2 M\text{pro} [8-11]. Of the 12 FDA approved drugs identified, darunavir, indinavir, saquinavir and tipranavir are HIV protease inhibitors, and
raltegravir is a HIV integrase inhibitor used to treat HIV infections. Three other drugs identified; diosmin, hesperidin and rutin, are flavonoids used in the treatment of vascular disease, velpatasvir and ledipasvir are used to treat chronic Hepatitis C, rosuvastatin is a statin, and bortezomib, a single boron atom compound [12], is an inhibitor of proteasomal functioning used in the treatment of relapsed multiple myeloma [13]. First, we generated complexes between the 12 FDA-approved drugs and dimeric SARS-CoV2 M\textsuperscript{pro} using a docking method. Subsequently, complexes were submitted to MD simulations coupled with MM/GBSA to elucidate the molecular mechanism by which the molecules were able to inhibit dimeric SARS-CoV2 M\textsuperscript{pro}. The analysis identified saquinavir based on its therapeutic potential against COVID-19.

2. Methods

2.1 Preparation of Systems

Twelve FDA-approved small drugs; darunavir (DB01264), indinavir (DB00224), saquinavir (DB01232), tipranavir (DB00932), diosmin (DB08995), hesperidin (DB04703), rutin (DB01698), raltegravir (DB06817), velpatasvir (DB11613), ledipasvir (DB09027), rosuvastatin (DB01098) and bortezomib (DB00188) were obtained from the DrugBank version 5.0 [14], and optimized at the AM1 level using Gaussian 09W software [15]. The X-ray structure of SARS-CoV2 M\textsuperscript{pro} (PDB code 6LU7) was used to build protein-ligand complexes.

2.2 Molecular Docking

The fourteen FDA-approved small compounds were coupled with dimeric SARS-CoV2 M\textsuperscript{pro} using AutoDock Tools 1.5.6 and AutoDock 4.2 programs [16]. Hydrogen atoms were added to ligand and protein atoms, and partial charges were assigned to receptor (Kollman) and ligand Gasteiger. The grid box was focused on the receptor with the following grid points: 70 x 70 x 70 Å in the x, y and z positions, respectively, and a grid space of 0.375 Å. Ligand placement was performed using a Lamarckian-genetic algorithm. The protein-ligand complex with the lowest binding energy was used to initiate MD simulations, and validation of the method was performed by replicating the experimental binding mode of co-crystallized ligand present on SARS-CoV2 M\textsuperscript{pro} (PDB code 6LU7).

2.3 MD Simulations, Binding Free Energy and Per-Residue Decomposition Calculations

MD simulations were performed using the AMBER16 software package [17] and ff14SB force field [18]. Ligand force fields were constructed employing AM1-BCC atomic charges and GAFF force field [19]. Each system was solvated using the TIP3P water model [20] in a 12.0 Å dodecahedral box, and neutralized with 0.10 M of NaCl. Once systems were equilibrated, triplicate 100-ns-long MD simulations were performed using an NPT ensemble at 310 K. The SHAKE algorithm [21] was employed to constrain bond at their equilibrium lengths, and temperature and pressure were preserved using the weak-coupling algorithm [22]. Electrostatic forces were defined using the PME method [23], and a 10 Å cut-off was designated for van der Waals interactions. Simulations were analyzed using AmberTools16 software. Images were built using PyMOL [24].

The MM/GBSA [25,26] approach was used to determine binding free energies (\(\Delta G_{\text{bind}}\)) of complexes and per-residue decomposition contributions, which were determined as described previously [27]. Prior to calculations, counterions and water molecules were removed over 500 snapshots at time intervals of 100 ps, and a salt concentration of 0.10 M was selected.

3. Results And Discussion

3.1 Convergence of MD Simulations

Evaluation of RMSD and R\(_G\) revealed that systems reached equilibrium in 10–20 ns with average RMSG and R\(_G\) values that fluctuated between 1.5 ± 0.2 and 2.4 ± 0.2 Å, and 25.7 ± 0.3 and 26.1 ± 0.2 Å, respectively (Table
1, supplementary material). Values determined here were similar to those previously observed for the bound dimeric system [7]. Therefore, the first 30 ns of the 100 ns simulation were excluded from further analyses.

### 3.2 MD Simulations of Ligand-Dimeric SARS-CoV2 M\(^{\text{pro}}\) Binding

MD simulations showed that ligands remained bound to both subunits of the dimer, with the exception of systems assessing rutin and ledipasvir with dimeric SARS-CoV2 M\(^{\text{pro}}\). In this case rutin diffused from both subunits of SARS-CoV2 M\(^{\text{pro}}\), and ledipasvir remained bound to one dimeric SARS-CoV2 M\(^{\text{pro}}\) catalytic site. Peptide-like inhibitor N3 was bound to subunit 1 via hydrophobic contacts involving T25, L27, H41, C44, T45, S46, M49 and Q189. N3 also established polar interactions with the side chain of Q189 (Fig. 1A). At subunit 2 inhibitor N3 was stabilized by contact with L27, H41, M49, N142, G143, S144, C145, M165, P168, D187 and Q189, and hydrogen bonds with backbone C145, and side chain S144 (Fig. 1B). Of these residues, T25, H41, M49, N142, G143, S144, C145, M165, P168, D187 and Q189 were observed in the co-crystallized complex (PDB code 6LU7).

Darunavir in subunit 1 was bound by L27, H41, M49, F140, N142, G143, S144, C145, H163, M165, D187 and Q189 via non-polar interactions, and formed hydrogen bonds with backbone G143 and D187 residues (Fig. 1C). On subunit 2, coordination of darunavir occurred through non-polar interactions with T25, H41, C44, S46, M49, N142, C145, M165, D187, R88 and Q189, and polar interactions with T25 and N142 side chains and backbone atoms of H41 and C44 (Fig. 1D).

Indinavir was stabilized at subunit 1 through non-polar interactions with H41, M49, M165, E166, P168, R188, Q189, A191 and Q192, and established polar interactions with the side chain of Q189 (Fig. 1E). On subunit 2, the ligand was coordinated by H41, M49, C145, M165, E166, L167, P168, A191 and Q192 through hydrophobic contacts, and by polar interactions with backbone and side chain atoms of E166 (Fig. 1F).

Saquinavir bound subunit 1 through non-polar interactions with T25, H41, S46, M49, F140, L141, N142, S144, C145, M165, E166, P168, D187 and Q189 with the side chain of Q189 (Fig. 2A). Saquinavir bound subunit 2 via non-polar interactions involving H41, V42, M49, F140, L141, N142, S144, C145, M165, E166, P168, D187 and Q189, and through polar interactions with side chain groups of N142 and Q189, and with backbone atoms of E166 (Fig. 2B).

Tripanivir bound subunit 1 through hydrophobic contacts with T25, T26, L27, H41, V42, C44, M49, N142, G143, S144, C145 and M165, and polar interactions with backbone atoms of G143 and T26 (Fig. 2C). On subunit 2, tripanivir was bound via polar interactions with T24, T25, L27, C44, T45, S46, M49, N142 and G143, and polar interactions with the side chain of S46 (Fig. 2D).

Interactions between diosmin and subunit 1 were stabilized through hydrophobic interactions with T25, L27, H41, M49, P52, F140, N142, G143, S144, C145, H163, M165, E166, R188 and Q189, polar interactions with backbone atoms of M49 and S144, and side chain atoms of H41 and E166 (Fig. 2E). On the subunit 2 diosmin bound H41, M49, M165, L167, P168, D187, R188, Q189 and Q192 via non-polar interactions, and backbone atoms of R188 through polar interactions (Fig. 2F).

Hesperidin bound subunit 1 through hydrophobic contacts with L27, H41, T45, C145, H164, M165, E166, L167, P168, D187, Q189, T190 and A191, and hydrogen bonds with the side chains of H41 and E166 (Fig. 3A). On subunit 2, hesperidin bound via hydrophobic interactions with L27, H41, M49, N142, C145, M165 and Q189, and formed polar interaction with the side chain of the latter residue (Fig. 3B).

Raltegravir bound subunit 1 through non-polar interactions with T25, L27, H41, T45, S46, M49 and N142 (Fig. 3C). On subunit 2, binding to raltegravir occurred through polar contacts with H41, M49, M165, D187, R188 and Q189, and hydrogen bonding with R188 (Fig. 3D). Velpatasvir was stabilized at subunit 1 through hydrophobic contacts with T25, L27, S46, M49, L50, G143, C145, Q189, T190 and A191, and by one hydrogen bond with the side chain of S46 (Fig. 3E). In contrast, at subunit 2 the ligand bound via non-polar interactions with T25, T26, L27, S46, M49, L50, N142, G143, P168, Q189, T190, A191, and polar interaction with backbone atoms of T26, Q189 and A191 (Fig. 3F).
Ledipasvir bound subunit 1 via hydrophobic contacts with L141, N142, Q189, T190, A191, and polar interactions with both the backbone and side chain of N142 (Fig. 4A).

Rosuvastatin was stabilized through hydrophobic interactions with T25, L27, H41, M49, N142, C145, H163, M165, E166, Q189 and Q192, and formed polar interaction with the side chain of the latter residue (Fig. 4B). At subunit 2 rosuvastatin was stabilized via hydrophobic interactions with T25, L27, H41, T45, N142, G143, C145, M165 and Q189 (Fig. 4C).

Bortezomib bound subunit 1 through hydrophobic contacts with L27, H41, M49, L141, N142, G143, S144, F140, C145, H163 and M165, and established polar interactions with the side chain of N142, and backbone atoms of G143 and L27 (Fig. 4D). At subunit 2, bortezomib bound L27, H41, C44, T45, A46, M49, M165, D187, R188, and Q189 via hydrophobic interactions, and formed hydrogen bonds with backbone atoms of R188, and the side chain of Q189 (Fig. 4E).

Binding was primarily stabilized via non-polar interactions involving L27, H41, M49 and M165 residues. T25, T26, H41, C44, S46, M49, N142, G143, S144, C145, E166, D187, R188, Q189, A191 and Q192 established polar interactions through their backbones or side chains with some of the compounds assessed (Fig. 2-4). H41 and C145 are part of the catalytic site, and H41, M49, G143, S144, M165, E166, D187, R188, Q189, A191 and Q192 form part of the substrate binding region [28,29], indicating that all ligands fit into their respective active sites. In addition, we observed that complexes involving each subunit were generally stabilized by an uneven number of residues. This suggested that the conformations of the two catalytic sites of the dimer were variable, which was a result not observed via crystallographic methods.

### 3.3 Free Energy of Binding

Affinity for complex formation was calculated using the MM/GBSA approach. We observed that all binding was thermodynamically favorable and occurred through the formation of non-polar interactions, van der Waals energy ($\Delta_{E_{vdw}}$) and non-polar free energy of desolvation ($\Delta G_{npol, sol}$). $\Delta G_{bind}$ values for compounds bound to the first subunit of dimeric SARS-CoV2 M$_{pro}$ demonstrated the following binding tendencies: saquinavir > tipranavir > darunavir > diosmin > rosuvastatin > indinavir > bortezomib > peptide-like inhibitor N3 > velpatasvir > hesperidin > raltegravir. $\Delta G_{bind}$ values associated with binding to the second subunit were as follows: saquinavir > indinavir > hesperidin > darunavir > velpatasvir = ledipasvir > peptide-like inhibitor N3 > raltegravir > diosmin > tipranavir = rosuvastin > bortezomib (Table 1). Differing affinity for each subunit is consistent with observed differences in the number of interactions involved in binding to each subunit, which were determined through structural analyses (Fig. 1-4). This highlights the importance of evaluating affinity to both subunits using end-point free energy methods. Binding tendency determined here is in agreement with a previous study in which enhanced inhibitory properties were associated with saquinavir relative to darunavir [30], but contrasting with the enhanced inhibitory activity experimentally determined for nelfinavir compared to saquinavir. This may suggest nelfinavir inhibits activity of more than one target [31]. Saquinavir and darunavir had increased affinity for dimeric SARS-CoV M$_{pro}$ than that which was previously determined for praziquantel, perampanel, ritonavir and nelfinavir using similar methodology, whereas affinity of darunavir was similar to that which had previously been reported for lopinavir [7].

Based on this analysis, it is clear that both saquinavir and darunavir, both known to possess potent antiviral protease inhibitory activity [32,33], are attractive anti-COVID-19 clinical drug candidates. The two drugs had stronger affinity for both subunits of M$_{pro}$ than that which was experimentally determined for peptide-like inhibitor N3, which displayed strong antiviral effects in the μM concentration range in SARS-CoV-2 virus-infected Vero cells [34]. Assessment of $\Delta G_{bind}$ values for indinavir and tipranavir indicated that they may also possess moderate activities against COVID-19. A comparison of the 12 FDA-approved compounds evaluated, after excluding ledispavir and rutin that exhibited ligand diffusion in one or both subunits, revealed that the worst candidates to inhibit activity of dimeric SARS-CoV M$_{pro}$ were raltegravir and bortezomib. These compounds had the greatest affinities of all inhibitors assessed via virtual screening, which employed docking studies involving monomeric SARS-CoV M$_{pro}$ [10,11].
Comparative analysis of the affinity tendency observed for three of the 12 evaluated compounds previously reported by Farag et al. (Darunavir > rosuvastatin > saquinavir) [8], Chen et al. (ledipasvir > velpatasvir) [9], Adem et al. (hesperdin > rutin > diosmin) [35], and Kumar et al. (tipranavir > raltegravir) [10] revealed discrepancies when compared with our findings. These observations highlight the degree to which the computational strategy employed to identify potential inhibitors of SARS-CoV M<sub>pro</sub> impacted affinity tendency, and underscored the utility of combining docking, MD simulations and end-point binding free energy methods.

3.4 Per-residue Free Energy Decomposition

Investigation of the residues contributing to Δ<sub>bind</sub> in ligands-dimeric SARS-CoV2 complex revealed that complex stabilization could generally be attributed to 5 to 14 residues (Table 2-4). Complex formation between dimeric SARS-CoV2 M<sub>pro</sub> and peptide-like inhibitor N3 involved T25, C44, T45 and S46 of subunit 1. The energetic contribution of N142, G143, S144, C145, M165, P168 and D187 residues were only observed when ligands bound subunit 2 (Table 2), while L27, H41, M49, and Q189 contributed to the stabilization of binding to both subunits. For darunavir, L27, F140, G143, S144 and H163 stabilized binding subunit 1, and T25, C44, S46 and R188 stabilized binding to subunit 2. H41, M49, N142, C145, M165, D187 and Q189 residues were involved in binding to both subunits.

For indinavir, R188 and Q189 contributed stabilized binding to subunit 1, whereas tC145 and L167 facilitated subunit 2 binding. H41, M49, M165, D166, P168, A191 and Q192 were involved in binding to both subunits. For saquinavir, T25 and S46 of subunit 1 stabilized binding, and V42 stabilized interactions involving subunit 2. H41, M49, F140, L141, N142, S144, C145, M165, D166, P168, D187 and Q189 contributed energetically to binding to both subunits. T26, H41, V42, S144, C145 and M165 residues of subunit 1, and T24, T45 and S46 of subunit 2, were involved in binding to tipranavir. T25, L27, C44, M49, N142 and C143 facilitated binding to both subunits of M<sub>pro</sub>. T25, L27, P52, F140, N142, G143, S144, C145, H163 and E166 stabilized diosmin binding to subunit 1, whereas L167 and P168 promoted binding to subunit 2. H41, M49, M165, R188 and Q189 contribute at both subunits of dimeric SARS-CoV2 M<sub>pro</sub> (Table 3).

T45, H164, E166, L167, P168, D187, T190 and A191 facilitated hesperidin-subunit 1 binding, and M49 and N142 exclusively facilitated binding to subunit 2. L27, H41, C145, M165 and Q189 of both subunits of dimeric SARS-CoV2 were involved in binding hesperidin (Table 3). T25, L27, T45, S46 and N142 of subunit 1 were determined to be the principal stabilizers of raltegravir binding, whereas that M165, D187, R188 and Q189 of subunit 2 promoted binding to the inhibitor. H41 and M49 were involved in binding both M<sub>pro</sub> subunits (Table 3). C145 was the only residue of subunit 1 involved in binding velpatasvir, while T26, N142 and P168 of subunit 2 stabilized binding. While T25, L27, S46, M49, L50, G143, Q189, T190 and A191 of both subunits were involved in binding (Table 3). Regarding ledipasvir, ligand only remained bound to subunit 2 via the energetic contributions of L141, N142, Q189 and T190 (Table 4). With regard to rosuvastatin, M49, H163, E166 and Q192 of subunit 1, while and T45 and G143 of subunit 2 stabilized interactions with ligands. L27, H41, N142, N145, M165 and Q189 of both subunits facilitated binding. For bortezomib was observed that F140, L141, N142, G143, S144, C145 and H163 stabilized ligand binding to subunit 1. C44, T45, S46, D187, R188 and Q189 stabilized ligand binding to subunit 2. However, L27, H41, M49 and M165 stabilized ligand binding to both subunits.

An analysis of residues that enhanced ligand binding affinity revealed that, in general, L27, T25, T26, H41, M49, V42, T45, L50, S46, F140, N142, G143, S144, C145, H163, M165, D166, P168, D187, R188, Q189, T190, A191 and Q192 significantly contributed to Δ<sub>bind</sub> values of some complexes, but only L27, H41, M49 and M165 were involved in protein-ligand complex formation consistently. This highlights the importance of residues that comprise the catalytic (H41) and substrate binding (M49 and M165) sites [28,29], and reveals the importance of the participation of other residues involved in ligand stabilization, which were also identified previously [7].

3.5 Principal Component Analysis (PCA)

PCA analysis allowed researchers to quantitatively approximate the degree of mobility change that occurred upon ligand complexation. Therefore, the trace of the diagonalized covariance matrix of backbone atoms was calculated for bound SARS-CoV2 M<sub>pro</sub> systems. This analysis showed that darunavir, hesperidin and raltegravir...
binding was linked to a reduced degree of conformational change of dimeric SARS-CoV2 M\textsuperscript{pro} relative to that which occurred when the apo state [7] of the protein was bound. Peptide-like inhibitor N3, indinavir, saquinavir, tipranavir, velpatasvir, and bortezomib binding to dimeric SARS-CoV2 M\textsuperscript{pro} produced a small increase in conformational mobility. However, diosmin and ledipasvir binding did not produce conformational change upon ligand binding. Importantly, binding of rosuvastatin increased the conformational mobility of dimeric SARS-CoV2 M\textsuperscript{pro}, which suggested binding of most compounds was not likely to significantly impact affinity for rosuvastatin (Table 1), while decreases in the predicted affinity for rosuvastatin could be expected as a result of favorable entropic components that affect the degree of conformational mobility upon complex formation.

4. Conclusion

Through a combination of structural data, docking and MD simulations using an MM/GBSA approach, previous research identified of new inhibitors (praziquatel and perampanel) of SARS-CoV2 M\textsuperscript{pro}. MD simulations used in combination with end-point free energy methods revealed that ligand binding was enhanced when dimeric SARS-CoV2 M\textsuperscript{pro}, rather than its monomeric form, was used. In this research, we elaborated upon previous work by employing docking and MD simulation studies coupled with the MM/GBSA approach to assess interactions between SARS-CoV2 M\textsuperscript{pro} and 12 FDA-approved drugs identified previously for their potential activity against COVID-19 via virtual screening of monomeric SARS-CoV2 M\textsuperscript{pro} and the peptide-like inhibitor, N3, which was demonstrated to have strong antiviral activity against COVID19 in vitro. Our results indicated that saquinavir is predicted to have a greater affinity for dimeric SARS-CoV M\textsuperscript{pro} than that which is predicted for praziquantel, perampanel, ritonavir, lopinavir or nelfinavir, using comparable methodology. Therefore, saquinavir shows great potential as a strong anti-COVID-19 therapeutic candidate, particularly because it displayed higher affinity for both subunits than peptide-like inhibitor N3. Although these data are insufficient for confirming antiviral activity, they provide a basis for future studies focused on in vitro and in vivo testing of viral activity.

Declarations

Acknowledgements

The work was supported by grants from CONACYT (CB-A1-S-21278) and SIP/IPN (20201015).

Competing interests

The authors declare no competing interests.

References

1. Xu, P. Chen, J. Wang, J. Feng, H. Zhou, X. Li, W. Zhong, P.J.S.C.L.S. Hao, Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission, Sci China Life Sci (2020).
2. Vastag, B., 2003. Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS. JAMA 290, 1695–1696.
3. Nukoolkarn, V., Lee, V. S., Malaisree, M., Aruksakulwong, O., & Hannongbua, S. (2008). Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CLpro inhibitors. Journal of theoretical biology, 254(4), 861-867.
4. Xu, Z., Peng, C., Shi, Y., Zhu, Z., Mu, K., Wang, X., & Zhu, W. (2020). Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation. bioRxiv. doi:https://doi.org/10.1101/2020.01.27.921627
Sang, peng; Tian, Shuhui; Meng, Zhaohui; Yang, Liquan (2020): Insight Derived from Molecular Docking and Molecular Dynamics Simulations into the Binding Interactions Between HIV-1 Protease Inhibitors and SARS-CoV-2 3CLpro. ChemRxiv. Preprint. https://doi.org/10.26434/chemrxiv.11932995.v1

Graziano, V., McGrath, W. J., Yang, L., & Mangel, W. F. (2006). SARS CoV Main Proteinase: The Monomer–Dimer Equilibrium Dissociation Constant. Biochemistry, 45(49), 14632-14641.

Martiniano Bello. Prediction of potential inhibitors of the dimeric SARS-CoV-2 main proteinase through the MM/GBSA approach, 06 April 2020, available at Research square https://doi.org/10.21203/rs.3.rs-21205/v1

Farag, Ayman; Wang, Ping; Ahmed, Mahmoud; Sadek, Hesham (2020): Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning. ChemRxiv. Preprint. https://doi.org/10.26434/chemrxiv.12003930.v3

Chen YW, Yiu CB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020;9:129. Published 2020 Feb 21. doi:10.12688/f1000research.22457.2

Kumar, Yogesh; Singh, Harvijay (2020): In Silico Identification and Docking-Based Drug Repurposing Against the Main Protease of SARS-CoV-2, Causative Agent of COVID-19. ChemRxiv. Preprint. https://doi.org/10.26434/chemrxiv.12049590.v1

Vega Valdez, Ivan Ricardo; Santiago-Quintana, José Martín; ROSALEZ, MELVIN; Farfan, Eunice; Soriano-Ursua, Marvin A. (2020): Theoretical Evaluation of Bortezomib and Other Boron-Containing Compounds as Inhibitors of SARS-CoV-2 Main Protease. ChemRxiv. Preprint. https://doi.org/10.26434/chemrxiv.12047346.v1

Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–2791

Frisch MJT, GW Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA, Jr, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Gyung SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas Ó, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ (2009) Gaussian Gaussian Inc.

Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Contr 2003; 10(5): 361-9.

Frisch MJT, GW Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA, Jr, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Gyung SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas Ó, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ (2009) Gaussian Gaussian Inc.

Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Contr 2003; 10(5): 361-9.

Wishart, D. S.; Feunang, Y. D.; Guo, A. C.; Lo, E. J.; Marcu, A.; Grant, J. R.; Sajed, T.; Johnson, D.; Li, C.; Sayeeda, Z.; Assempour, N.; Lynkkanen, I.; Liu, Y.; Maciejewski, A.; Gale, N.; Wilson, A.; Chin, L.; Cummings, R.; Le, D.; Pon, A.; Knox, C.; Wilson, M., DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018, 46 (D1), D1074-D1082

Bello, Advances in theoretical studies on the design of single boron atom compounds, Curr. Pharm. Des. 29 (2018) 3466–3475

10.1039/C5CP05566A

Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Contr 2003; 10(5): 361-9.

Richardson PG, Hideshima T, Anderson KC. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Contr 2003; 10(5): 361-9.
units of kcal/mol).

| System                                      | $\Delta E_{vdw}$ | $\Delta E_{ele}$ | $\Delta G_{ele,sol}$ | $\Delta G_{npol,sol}$ |
|---------------------------------------------|------------------|------------------|-----------------------|-----------------------|
| Dimmeric SARS-CoV2 M$^{\text{pro}}$         |                  |                  |                       |                       |
| SARS-CoV2$_{\text{sub1}}$-inhibitor N3      | -42.2 ± 7.0      | -14.7 ± 6.0      | 36.7 ± 7.0            | -5.4 ± 0.9            |
| SARS-CoV2$_{\text{sub2}}$-inhibitor N3      | -49.6 ± 7.0      | -30.9 ± 10.0     | 55.9 ± 10.0           | -6.3 ± 0.7            |
| SARS-CoV2$_{\text{sub1}}$-darunavir          | -54.0 ± 5.0      | -19.4 ± 6.0      | 40.3 ± 6.0            | -6.8 ± 0.6            |
| SARS-CoV2$_{\text{sub2}}$-darunavir          | -45.7 ± 9.0      | -18.8 ± 6.0      | 36.4 ± 7.0            | -5.8 ± 1.0            |
| SARS-CoV2$_{\text{sub1}}$-indinavir          | -39.3 ± 5.0      | -197.2 ± 22.0    | 213.2 ± 22.0          | -4.9 ± 0.5            |
| SARS-CoV2$_{\text{sub2}}$-indinavir          | -46.6 ± 5.0      | -259.9 ± 23.0    | 273.8 ± 23.0          | -6.0 ± 0.6            |
| SARS-CoV2$_{\text{sub1}}$-saquinavir         | -62.4 ± 4.0      | -116.6 ± 7.7     | 142.5 ± 7.0           | -7.3 ± 0.3            |
| SARS-CoV2$_{\text{sub2}}$-saquinavir         | -60.9 ± 4.0      | -125.0 ± 9.0     | 151.2 ± 10.0          | -7.6 ± 0.5            |
| SARS-CoV2$_{\text{sub1}}$-tipranavir         | -54.9 ± 3.0      | 44.5 ± 7.4       | -25.1 ± 7.0           | -6.6 ± 0.3            |
| SARS-CoV2$_{\text{sub2}}$-tipranavir         | -33.7 ± 5.0      | 65.0 ± 12.0      | -46.6 ± 11.0          | -4.6 ± 0.7            |
| SARS-CoV2$_{\text{sub1}}$-diosmin            | -54.1 ± 4.0      | -26.7 ± 8.0      | 54.0 ± 8.0            | -6.7 ± 0.3            |
| SARS-CoV2$_{\text{sub2}}$-diosmin            | -40.2 ± 6.0      | -40.3 ± 16.0     | 62.0 ± 14.0           | -5.2 ± 0.4            |
| SARS-CoV2$_{\text{sub1}}$-hesperidin         | -45.8 ± 4.0      | -21.8 ± 10.0     | 50.2 ± 9.0            | -5.8 ± 0.5            |
| SARS-CoV2$_{\text{sub2}}$-hesperidin         | -57.4 ± 3.0      | -26.0 ± 10.0     | 53.6 ± 8.0            | -6.6 ± 0.2            |
| SARS-CoV2$_{\text{sub1}}$-rutin              | ND               | ND               | ND                    | ND                    |
| SARS-CoV2$_{\text{sub2}}$-rutin              | ND               | ND               | ND                    | ND                    |
| SARS-CoV2$_{\text{sub1}}$-raltegravir        | -28.0 ± 6.0      | -13.6 ± 7.0      | 28.8 ± 7.0            | -3.7 ± 0.7            |
| SARS-CoV2$_{\text{sub2}}$-raltegravir        | -40.3 ± 3.0      | -11.6 ± 5.0      | 30.9 ± 4.0            | -4.5 ± 0.3            |
| SARS-CoV2$_{\text{sub1}}$-velpatasvir        | -38.9 ± 8.0      | -14.2 ± 7.0      | 33.5 ± 8.0            | -4.8 ± 0.9            |
| SARS-CoV2$_{\text{sub2}}$-velpatasvir        | -47.8 ± 5.0      | -25.6 ± 8.0      | 47.5 ± 7.0            | -6.0 ± 0.5            |
| SARS-CoV2$_{\text{sub1}}$-ledipasvir         | ND               | ND               | ND                    | ND                    |
| SARS-CoV2$_{\text{sub2}}$-ledipasvir         | ND               | ND               | ND                    | ND                    |
| SARS-CoV2$_{\text{sub1}}$-rosuvastatin       | -41.3 ± 4.0      | 58.0 ± 11.0      | -41.4 ± 10.0          | -5.4 ± 0.5            |
| SARS-CoV2$_{\text{sub2}}$-rosuvastatin       | -36.0 ± 6.0      | 60.8 ± 12.0      | -40.2 ± 11.0          | -4.9 ± 0.7            |
| SARS-CoV2$_{\text{sub1}}$-bortezomib         | -38.1 ± 3.3      | 65.4 ± 14.0      | -48.4 ± 11.0          | -4.7 ± 0.4            |
| SARS-CoV2$_{\text{sub2}}$-bortezomib         | -32.9 ± 4.3      | 73.1 ± 11.0      | -53.4 ± 11.0          | -4.3 ± 0.6            |

**Table 2.** Per-residue free energies of ligand-dimeric SARS-CoV2 M$^{\text{pro}}$ complexes (values kcal/mol).
| Residue | Lig1_{Sub2} | Lig1_{Sub1} | Lig2_{Sub1} | Lig2_{Sub2} | Lig3_{Sub1} | Lig3_{Sub2} | Lig4_{Sub1} | Li |
|---------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|----|
| T24     |             |             |             |             |             |             |             |    |
| T25     | -0.604      |             | -0.740      |             | -0.567      |             |             |    |
| T26     |             |             |             |             |             |             |             |    |
| L27     | -0.550      | -0.569      | -0.669      |             |             |             |             |    |
| H41     | -1.806      | -0.925      | -1.217      | -1.955      | -0.595      | -0.785      | -0.865      | -1 |
| V42     |             |             |             |             |             |             | -0.104      |    |
| C44     | -1.030      |             | -0.646      |             |             |             |             |    |
| T45     | -0.818      |             |             |             |             |             |             |    |
| S46     | -0.603      |             | -0.658      |             | -0.659      |             |             |    |
| M49     | -2.051      | -2.381      | -1.779      | -2.172      | -0.888      | -0.589      | -2.127      | -1 |
| F140    |             | -1.353      |             |             | -0.577      | -0.104      |             |    |
| L141    |             |             |             |             | -0.578      | -0.104      |             |    |
| N142    | -1.571      | -2.836      | -0.786      |             | -1.080      |             | -1.005      | -1 |
| G143    | -0.986      | -2.027      |             |             |             |             |             |    |
| S144    | -0.651      | -0.624      |             |             | -0.794      | -0.104      |             |    |
| C145    | -1.297      | -0.717      | -0.506      | -0.633      | -0.601      |             |             |    |
| H163    |             | -0.686      |             |             |             |             |             |    |
| M165    | -1.214      | -1.549      | -2.264      | -3.263      | -4.215      | -3.455      |             | -3 |
| D166    |             |             | -0.683      | -2.464      | -0.810      |             |             | -0 |
| L167    |             |             |             |             | -0.545      |             |             |    |
| P168    | -0.719      |             | -0.547      | -0.652      | -1.085      |             |             | -1 |
| D187    | -0.650      | -0.556      | -1.468      |             |             | -0.971      |             | 0  |
Table 3. Per-residue free energies of ligand-dimeric SARS-CoV2 M\(^{\text{pro}}\) complexes (values kcal/mol).

| Residue | Lig6\(_{\text{Sub1}}\) | Lig6\(_{\text{Sub2}}\) | Lig7\(_{\text{Sub1}}\) | Lig7\(_{\text{Sub2}}\) | Lig8\(_{\text{Sub1}}\) | Lig8\(_{\text{Sub2}}\) | Lig5 |
|---------|----------------|----------------|----------------|----------------|----------------|----------------|-----|
| T25     | -0.511         |               |               |               | -0.712         | -0.7           | -0.7 |
| T26     |               |               |               |               |               |               |     |
| L27     | -0.651         | -0.840        | -0.782        | -0.782        |               |               | -0.6 |
| H41     | -2.058         | -0.927        | -1.461        | -1.856        | -0.631         | -1.276         |     |
| T45     |               | -0.593        |               | -0.899        |               |               |     |
| S46     |               |               |               | -1.504        |               | -0.7           |     |
| D48     |               |               |               |               |               |               |     |
| M49     | -2.339         | -1.860        | -1.189        | -1.567        | -1.032         | -2.1           |     |
| L50     |               |               |               |               |               | -1.9           |     |
| P52     | -0.509         |               |               |               |               |               |     |
| F140    | -0.550         |               |               |               |               |               |     |
| N142    | -0.686         |               |               | -0.932        | -0.608         |               |     |
| G143    | -0.724         |               |               |               |               | -0.5           |     |
| S144    | -1.506         |               |               |               |               |               |     |
| C145    | -1.713         | -0.989        | -0.967        |               |               | -0.7           |     |

Inhibitor N3=lig1, darunavir=lig2, indinavir=lig3, saquinavir=lig4, tipranavir=5
| Residue | Free Energy (kcal/mol) |
|---------|------------------------|
| H163    | -2.198                 |
| H164    | -0.517                 |
| M165    | -3.400  -1.907  -2.454  -1.658  -1.931 |
| E166    | -0.858                 |
| L167    | -0.851  -0.677         |
| P168    | -0.983                 |
| D187    | -1.274  -0.678         |
| R188    | -0.945  -0.920         |
| Q189    | -1.648  -2.271  -2.137  -1.799  -2.550  -1.5 |
| T190    | -0.734                 |
| A191    | -0.878                 |
| Q192    | -0.656                 |

diosmin=lig6, hesperidin=lig7, raltegravir=lig8 and velpatasvir=lig9

**Table 4.** Per-residue free energies of ligand-dimeric SARS-CoV2 M\(^{\text{pro}}\) complexes (values kcal/mol).
| Residue | Lig10_{Sub2} | Lig11_{Sub1} | Lig11_{Sub2} | Lig12_{Sub1} | Lig12_{Sub2} |
|---------|--------------|--------------|--------------|--------------|--------------|
| T25     | -0.614       | -0.522       |              |              |              |
| L27     | -0.512       | -1.001       | -1.365       | -0.573       |              |
| H41     | -1.226       | -1.746       | -0.579       | -1.622       |              |
| C44     |              |              |              | -0.608       |              |
| T45     |              | -0.767       |              | -0.508       |              |
| S46     |              |              |              | -0.701       |              |
| M49     | -0.707       |              | -0.558       | -3.131       |              |
| F140    |              |              |              | -0.980       |              |
| L141    | -1.688       |              |              | -0.534       |              |
| N142    | -3.207       | -0.830       | -1.403       | -2.251       |              |
| G143    |              | -1.142       | -3.204       |              |              |
| S144    |              |              |              | -0.866       |              |
| C145    | -0.918       | -1.131       | -3.803       |              |              |
| H163    | -0.539       |              | -1.775       |              |              |
| M165    | -4.104       | -1.833       | -0.912       | -0.942       |              |
| E166    |              | -0.587       |              |              |              |
| D187    |              |              |              | -1.333       |              |
| R188    |              |              |              | -0.589       |              |
| Q189    | -1.656       | -2.145       | -1.485       | -1.798       |              |
| T190    | -1.785       |              |              |              |              |
| A191    | -2.481       |              |              |              |              |
| Q192    |              | -2.258       |              |              |              |
ledipasvir=lig10, rosuvastatin=lig11, bortezomib=lig12

Figures
Figure 1

Interactions between complexes comprised of ligands and dimeric SARS-CoV2 Mpro. Peptide-like inhibitor N3 bound to subunit 1 (A) and 2 (B), darunavir bound to subunit 1 (C) and 2 (D), and indinavir bound to subunit 1 (E) and 2 (F) of dimeric SARS-CoV2 Mpro are shown. Each complex resembles the most populated complex generated via a molecular docking simulation. The receptor is shown in the green cartoon representation, interacting residues are shown with green sticks, and the ligand is shown using a ball and stick representation. Figure was constructed with PyMOL 0.99rc6 [24].
Figure 2

Interaction map of ligand and dimeric SARS-CoV2 Mpro complex formation. Saquinavir bound to subunit 1 (A) and 2 (B), tripanivir bound to subunit 1 (C) and 2 (D), and diosmin bound to subunit 1 (E) and 2 (F) of dimeric SARS-CoV2 Mpro are shown.
Figure 3

Interaction map of ligand and dimeric SARS-CoV3 Mpro complex formation. Hesperidin coupled to subunit 1 (A) and 2 (B), raltegravir bound to subunit 1 (C) and 2 (D), and velpastir bound subunit 1 (E) and 2 (F) of dimeric SARS-CoV2 Mpro.
Figure 4
Interaction map of ligand and dimeric SARS-CoV2 Mpro. Ledipasvir bound subunit 1 (A), rosvastatin bound to subunit 1 (C) and 2 (D), bortezomib bound subunit 1 (E) and 2 (F) of dimeric SARS-CoV2 Mpro.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supplementarymaterial.pdf